Reading list: worthwhile terms of service?

Abstract:
Not all digital fine print
exculpates liability: some exhorts users to perform before the
consumer relationship has soured.
We promise to choose strong passwords (and hold
them private); to behave civilly on
social networks; to refrain from streaming shows
and sports; and to avoid
reverse-engineering code (or, worse, deploying deadly bots).
In short: consumers are apparently
regulated by digital fine print, though it’s
universally assumed we don’t read
it , and even if we did, we’ll never be sued for failing
to perform.
On reflection, this ordinary
phenomenon is perplexing. Why would firms persist in
deploying uncommunicative
behavioral spurs? The conventional answer is that fine
print acts as an option, drafted by
uncreative, guild-captured lawyers. Through
investigation of several sharing
economy firms, and discussions with a variety of
lawyers in this space, I show that
this account is incomplete. Indeed, I identify and
explore examples of innovative fine
print that appears to really communicate with and
manage users.
These firms have cajoled using
contracts by trading on their brands and identities, and
by giving up on certain exculpatory
defenses common to digital agreements. I argue
that the result is a new form of
relational contracting, taking on attributes of both mass
market adhesion contracts and more
long-term deals.
A fascinating piece, especially for me (because I
participated heavily in drafting the Terms of Service for the Archive of Our
Own, where we had similar human-readability/user-friendly goals though a
nonprofit, noncommercial commitment). 
Hoffman concludes that ToS can communicate with users when they are
brand-congruent, but I would have put it differently: people are more likely to
learn the actual contents of the ToS when the site promotes knowledge of the
terms as part of its interactions with users (maybe even part of its branding).  The examples he uses also often involved soliciting
feedback from users, which itself is a form of disclosure/communication that
goes beyond normal promulgation of the ToS/use of checkboxes.

from Blogger http://ift.tt/2v0aaqY

Posted in Uncategorized | Tagged , | Leave a comment

The South (Butt) remembers

Via Mark Lemley. How should this fare? Better than the Starks, one hopes.

from Blogger http://ift.tt/2f8I3kg

Posted in Uncategorized | Tagged | Leave a comment

Seen around town(s), TM and right of publicity issues

From Cambridge:

Cola scented stickers in Coke-shaped bottle

Pies that make even the tiniest hands feel huge

 Also, I didn’t manage to grab a picture of the “Legally Brunette” shirt in the Law School Coop, but I wonder about that one too.

And eagle-eyed correspondent DM sent this one in from NYC:

F*ck Amazon, Fishs Eddy is prime! with prime in Amazon font/arrow

from Blogger http://ift.tt/2hh49Sc

Posted in Uncategorized | Tagged , , | Leave a comment

Seen around town(s), TM and right of publicity issues

From Cambridge:

Cola scented stickers in Coke-shaped bottle

Pies that make even the tiniest hands feel huge

 Also, I didn’t manage to grab a picture of the “Legally Brunette” shirt in the Law School Coop, but I wonder about that one too.

And eagle-eyed correspondent DM sent this one in from NYC:

F*ck Amazon, Fishs Eddy is prime! with prime in Amazon font/arrow

from Blogger http://ift.tt/2hh49Sc

Posted in Uncategorized | Tagged , , | Leave a comment

When life gives you Lemonade: court preserves copyright complaint against Beyoncé

Estate of Barré v. Carter, No. 17-1057, 2017 WL 3188489
(E.D. La. Jul. 25, 2017)
Plaintiffs alleged that they owned in the copyright in two
YouTube videos created by Anthony Barré, a performance comedian and music
artist from New Orleans whose voice “was a unique instrument and inextricably
linked to his performance art.” 
Defendants released the song “Formation,” which used three phrases from
Anthony Barré’s works, “What happened at the New Orleans,” “Bitch I’m back, by
popular demand,” and “Oh yeah baby. I like that.”  Barré’s voice, performance, and words were
also allegedly “used and exploited” during the “Formation World Tour,” for example,
“Oh yeah baby, I like that” was used during the introductory performance of
“Formation,” and defendants allegedly utilized other performers to imitate
Anthony Barré’s voice and cadence in saying, “Bitch I’m Back by Popular Demand”
before defendant Carter appeared onstage. 
Plaintiffs sued for copyright infringement, false endorsements under the
Lanham Act, violations of the Louisiana Unfair Trade Practices Act (“LUTPA”),
and unjust enrichment under Louisiana law. 
Here, the district court understandably refuses to dismiss the copyright
claim on the pleadings, and inexplicably refuses to dismiss the other claims as
preempted/precluded by Dastar/barred
by the First Amendment.
Defendants argued that their purpose was transformative,
using the short clips to “create the tone, mood, setting and location of the
New Orleans-themed ‘Formation.’ ” 
Defendants disagreed that this could be transformative, and that the
original work wasn’t altered as in previous “appropriation” art cases where
fair use is found ((a) hunh? (b) taking little bits and mixing them with others
is alteration in my book, (c) I wouldn’t call this an appropriation art
case unless you want to merge that subset with transformative use cases in general).  Other bobbles aside, the court
concludes that enough has been pled to go forward on the question of
transformativeness and of fair use.  And
it correctly rejects plaintiffs’ bizarre idea that fair use doesn’t apply in
sound recording cases because of Bridgeport
Films
.
False endorsement: Plaintiffs pointed to Facenda v. NFL
Films, arguing that the court allowed a false endorsement case over use of a
voice “ when the promotional video and video game at issue were used for
commercial purposes.”  [Here we see part
of the problem of the chaos of false endorsement/publicity claims: the
plaintiff, however misleadingly, gets to ignore the distinction between
advertising and non-advertising uses.] 
The court found that such a claim could be viable. [But that’s not the
relevant question.  False endorsement is
a potentially viable claim; the question is, however, whether copying an
author’s work, especially outside an ad and as part of another creative work,
can itself constitute the relevant act supporting a false endorsement claim.  Dastar and
other cases indicate that it can’t.  It’s
also worth noting that the Copyright Act deliberately allows imitation of sound
recordings, which isn’t within the scope of the sound recording reproduction
right, so allowing a claim based on soundalikes not used in advertising (as
alleged here) also creates a direct conflict with the Copyright Act.]  The court held that it was enough to allege
that Barré’s voice and words were distinctive and recognized by consumers and
the media, which “caused consumer confusion regarding involvement or approval
of his estate” in “Formation,” the “Lemonade” album, and the “Formation World
Tour.”
The court distinguished Oliveira v. Frito-Lay because
plaintiffs alleged (1) that defendants imitated Barré’s voice, and (2) that
defendants used Barré’s voice in a way that created consumer confusion about
endorsement.  (2) of course merely
restates the theory rejected in Oliveira and doesn’t distinguish the case at
all; (1) doesn’t really address why a performance can be a trademark for
itself, which is the basic problem of such claims—again, especially as applied
to non-ad uses (which just multiplies the copyright conflicts).
Defendants correctly noted that, under Rogers, only an explicitly misleading non-advertising use escaped
First Amendment protection, and that explicit means explicit.  The court disagreed with the latter part of
this argument.  “For example, Plaintiffs
allege in the amended complaint that the ‘conduct of Defendants has been
willful from the inception of the creation of “Formation” and “Lemonade.”’ ” [That’s
not what “explicit” means.  It is not a
synonym for “intentional.”  Otherwise Rogers would have come out very
differently.  “Explicit” means falsely
claiming authorization, not remaining silent, which at most could be an
implicit claim.]  The allegations that
defendants “intentionally and unlawfully copied the unique and original voice
and words of Anthony Barré” to use as the “defining introduction of the song
‘Formation,’ ” “used and exploited” Anthony Barré’s voice and words during the
live performances by having another person imitate his voice and cadence, and “failed
to give credit or compensation in an ‘unethical, misleading, false, unfair and
deceptive’ manner” somehow substituted for explicitness.
Given this ruling, it’s not surprising that the Louisiana
Unfair Trade Practices Claim also survived, though of course it also has
copyright preemption/First Amendment problems that match up with the Dastar/Rogers problems of the federal claims.  Plaintiffs alleged misappropriation that went
beyond copyright because defendants acted “unethically, wrongfully and
fraudulently.”  [The “going beyond” alleged
consists entirely of the copying and its inherent effects.  “Profit” isn’t an extra element, nor are all
those adverbs, and the alleged misrepresentation is again based solely on the
copying as misrepresentation.] 
An unjust enrichment claim was dismissed as duplicative.

from Blogger http://ift.tt/2uQPhNl

Posted in Uncategorized | Tagged , , , | Leave a comment

When state consumer protection is narrower than federal

Natreon, Inc. v. Ixoreal Biomed, Inc., 2017 WL 3131975, No.
16-4735 (D.N.J. Jul. 21, 2017)
Natron sued defendant/counterclaimant/third-party plaintiff SKP
and defendant Ixoreal, alleging false advertising and unfair competition in
connection with an extract used in holistic and alternative medicines: KSM-66,
which is derived from the root of the ashwagandha plant. SKP filed three counterclaims,
alleging that Natreon also engaged in false advertising and unfair competition in
selling its competing product. SKP also filed a complaint against third-party
defendant NutraGenesis. Natreon successfully moved to dismiss SKP’s
Counterclaim for violation of the New Jersey Consumer Fraud Act.

SKP’s counterclaims alleged a number of false statements about Natreon’s
product, patent protection, and production processes.  In addition, SKP alleged that Natreon tried to
recruit SKP into engaging in price collusion and engaged in unfair competition
by threatening meritless litigation on several occasions.  SKP also alleged that both Natreon and
NutraGenesis engaged in deceptive acts in an attempt to obtain confidential
information, by posing as prospective customers.
Natreon successfully argued that SKP didn’t allege that it
suffered a consumer-like injury, as required for an NJCFA violation.  While neither “the statute nor the New Jersey
Supreme Court has explained with any precision who constitutes a consumer,” the
Third Circuit has advised that “the entire thrust of the [statute] is pointed
to products and services sold to consumers in the popular sense.” Thus, the
NJCFA has only been applied to business entities “who purchase goods and
services for use in their business operations,” as, for example, desk
chairs.  The alleged wrongdoing here
wasn’t consumer-oriented and the harm was not consumer-like.
The court also struck SKP’s affirmative defense of failure
to mitigate damages, which wasn’t a recognized defense to a Lanham Act claim or
the coordinate common-law claims.

from Blogger http://ift.tt/2h97pyM

Posted in Uncategorized | Tagged , | Leave a comment

SDNY declines to extend ONY to press releases about studies

Mimedx Group, Inc. v. Osiris Therapeutics, Inc., No. 16 Civ.
3645, 2017 WL 3129799 (S.D.N.Y. Jul. 21, 2017)
The parties compete in the wound care biologics market for
tissue-graft products.  Mimedx makes
“EpiFix,” “a tissue graft processed from [a dehydrated] human amniotic membrane
that is derived from donated placentas using [Plaintiff’s] proprietary
technology, including its Purion process.” EpiFix is designed to help “reduce
inflammation, enhance healing, and reduce scar tissue formation.” Osiris (cool
name), its direct competitor, makes Grafix, “a cryopreserved placental
membrane” used to treat acute and chronic wounds.
A comparative study conducted in Montana was eventually
published in the peer-reviewed journal Wound Repair and Regeneration. Osiris
published a press release on its website touting the results of the study.  Mimedx argued that statements in this press
release, as well as in an Osiris brochure, violated the Lanham Act and New York
G.B.L. §§249, 250.
First, the court found that the press release and the
brochure were properly alleged to be “commercial advertising or promotion.”  Osiris argued that its statements weren’t
commercial speech under ONY, Inc. v. Cornerstone Therapeutics, Inc., 720 F.3d
490 (2d Cir. 2013).  ONY held that a
medical article’s “contents [we]re not actionable under the Lanham Act” because
statements in scientific literature “are more closely akin to matters of
opinion, and are so understood by the relevant scientific communities.” But
here, Mimedx wasn’t challenging the study, but rather the press release, which
allegedly misrepresented the study, and the brochure, which wasn’t even
reporting on the study. These were “statements in commercial materials directed
principally to consumers, not statements in scientific materials directed to
scientists.”  In ONY, the court of appeals highlighted that the plaintiff there
didn’t allege that the defendant’s promotional materials misstated the relevant
article’s conclusions. The plaintiff here did. 
The “mere fact that the Press Release and the Brochure touch on topics
of scientific debate does not trigger ONY
immunity and disqualify them as commercial speech.”  Were that so, the Lanham Act would hardly
ever be enforceable.
Likewise, Mimedx adequately pled sufficient dissemination to
the relevant public, even though it didn’t plead the number of copies
distributed or the exact scope of the target market.  “The touchstone of whether a defendant’s
actions may be considered ‘commercial advertising or promotion’ under the
Lanham Act is that the contested representations are part of an organized
campaign to penetrate the relevant market.” 
Mimedx identified the relevant market as “the wound biologics market,”
and alleged distribution of the press release to current and prospective
customers, including specific wound treatment centers.  Many of the further details would be
difficult to identify without discovery; Mimedx had done enough to plead
plausibly.
Finally, for the most part, Mimedx plausibly alleged falsity
or misleadingness.  In terms of the press
release’s claims that the study showed “that Grafix has demonstrated superior
outcomes to EpiFix,” the study itself indicated that, “as to certain types of
ulcer wounds, EpiFix closed the same number as or slightly more than did
Grafix; that is, for some wounds EpiFix is arguably equally if not slightly
superior to Grafix, according to this metric.” 
Whether the press release statement was in fact deceptive because of the
overstatement couldn’t be resolved at this stage.
Similarly, the brochure claimed that (i) “A Chronic Wound
Needs: … Viable Cells”; (ii) EpiFix’s Purion process “destroys endogenous
tissue viable cells” and lacks the “presence of viable cells”; and (iii)
“Grafix provides everything you need for treating chronic wounds” such as
“viable cells.”  Mimedx claimed that
these statements were misleading because, “[w]hile viable cells can be
beneficial for wound healing, viable cells in a placental derived tissue graft
like Grafix are not necessary for effective wound healing,” and indeed, “viable
cells added to a chronic wound through an allograft die quickly upon
introduction to the wound or migrate away from the wound site,” and thus have a
“minimal contribution on the effectiveness of the allograft.” A reasonable
consumer could understand the brochure to be claiming that viable cells played
an important, even vital, role in the efficacy of tissue grafts and that EpiFix
lacks such cells while Grafix contains them.  Assuming the truth of Mimedx’s allegations,
this could deceive consumers.  Similar
reasoning applied to the brochure’s claims that EpiFix had a “high level” of Matrix
Metaloproteases (MMPs) while Grafix had low levels, and that MMPs were “not …
desirable” for wound repair.  Mimedx
alleged that the MMPs in EpiFix were inactive and thus harmful, making the
claim of deceptiveness plausible.

Finally, the brochure claimed that EpiFix’s Purion process “ ‘causes significant
alterations’ to the extracellular structural matrix (‘ECM’) of the amniotic
cells, such that the ECM is no longer ‘intact,’ ” which Mimedx alleged was
literally false.  Osiris argued that, to
plead literal falsity, Mimedx was required to identify “studies, literature, or
other [scientific] bas[e]s” for its factual assertion. The court declined to
impose such a requirement.

Similarly, the motion to dismiss §§ 349 and 350 G.B.L.
claims was denied. You might wonder whether this conduct was “consumer-oriented,”
but the parties agreed that this was basically the same question as “commercial
advertising or promotion” (sort of weird), so that was that at this stage.  Still, to the extent that the end users are
members of the general public, I can see an impact on the public from falsity
about these medical products.

from Blogger http://ift.tt/2h8ULjr

Posted in Uncategorized | Tagged , | Leave a comment

Purple haze: court declines to recognize contributory false advertising claim

Purple Innovations, LLC v. Honest Reviews, LLC, No.
2:17-cv-138, 2017 WL 3172810 (D. Utah Jul. 25, 2017)

Mostly a jurisdiction case, but defendant GhostBed also
successfully moved to dismiss Purple Innovations’ claim for contributory false
association and false advertising. 
Although the court acknowledged that (1) other circuits have recognized
contributory liability under §43(a)(1)(B) and that (2) courts in Utah have
recognized contributory infringement liability, it nonetheless declined “to
extend” the Lanham Act to allow such an action, with no further analysis.  Look, someone’s got to be the first—or at
least should make an argument about why there shouldn’t be contributory
liability for false advertising when the rest of the surrounding apparatus is the
same as for infringement.

from Blogger http://ift.tt/2tPgjro

Posted in Uncategorized | Tagged , | Leave a comment

The hymn of Axiom: failure to disclose in FX trades doesn’t violate consumer protection law

Axiom Investment Advisors, LLC v. Deutsche Bank AG, 2017 WL
590320, No. 15 Civ. 9945 (S.D.N.Y. Feb. 13, 2017)
Deutsche Bank allegedly delayed execution of electronically
matched trade orders in the foreign exchange (FX) market in order to benefit
from market movements, known as “Last Look.” 
Axiom sued for breach of contract, breach of the implied covenant of
good faith and fair dealing, violations of N.Y. General Business Law §§ 349 and
350, and unjust enrichment.
The FX market is “the largest and most actively traded
financial market in the world, with global trades averaging $5.3 trillion per
day.” It mostly works through bilateral contracts, in which large banks such as
Deutsche Bank represent the “sell side” and act as liquidity providers or
market makers. Most FX trades occur on electronic trading platforms, with price
and quantity data reflecting limit orders placed by liquidity providers.  This data stream is constantly updated—limit orders
are filled or withdrawn within milliseconds. 
Deutsche Bank trades on both single-dealer and multi-dealer platforms; on
the latter, it’s only one of many liquidity providers.  Its single-dealer platform is called
Autobahn, which claims to provide “competitive and reliable prices in over 200
currency pairs” with “dynamically priced executable streaming prices customized
to suit each client’s requirements.”
Beginning in 2003, Deutsche Bank allegedly arranged for the
matching algorithms used by Autobahn and other networks to include an
unnecessary delay of anywhere from several hundred milliseconds to several
seconds. During this time, Deutsche Bank monitored the market movement and if
it moved against Deutsche Bank too much, Deutsche Bank would either reject the
matched order or execute it at the new price. Deutsche Bank allegedly never
directly disclosed Last Look to buy-side FX market participants. The process of
matching orders is undisclosed to market participants; “buy-side market
participants have no way of knowing whether any of their trades were delayed by
Deutsche Bank’s use of Last Look or whether Deutsche Bank reneged on any of
their matched orders.” Although reports about this practice surfaced “several
years ago,” the liquidity providers “said at that time that Last Look was
necessary to ensure that multiple trades were not executed on a single order,”
which the complaint alleged was pretextual and misleading.
The complaint stated a claim for breach of contract arising
out of transactions on Autobahn because the contract between the parties didn’t
unambiguously permit Last Look; so too with transactions on other networks (for
which there was no express contract between the parties).  The claim for breach of the implied covenant
of good faith and fair dealing was dismissed as redundant.  The court dismissed the claim for unjust
enrichment relating to the Autobahn transactions (because of the existence of the
contract) but not for the multi-dealer transactions.


The state consumer protection claims under N.Y. Gen. Bus. Law §§ 349, 350 were
dismissed because FX trading wasn’t consumer-oriented conduct.  Conduct is consumer oriented if it has “a
broader impact on consumers at large,” and consumers are “those who purchase
goods and services for personal, family or household use.” “Transactions
between businesses or sophisticated parties that do not affect average
consumers do not constitute consumer-oriented conduct.” Similar to securities,
FX is traded “as investments, not as goods to be ‘consumed’ or ‘used.’ ” 

from Blogger http://ift.tt/2vbEHDJ

Posted in Uncategorized | Tagged , , | Leave a comment

Deceive, inveigle, obfuscate–false discount claims still don’t cause cognizable injury

Mulder v. Kohl’s Department Stores, Inc., — F.3d —-,
2017 WL 3167620, No. 16-1238 (1st Cir. Jul. 26, 2017)
Mulder bought several items that listed both purchase prices
and significantly higher “comparison prices.” Mulder alleged that these
comparison prices were inflated and invented, and that Kohl’s misled
unsuspecting consumers about the quality of its products. The court of appeals
affirmed the district court’s grant of a motion to dismiss.  She simply didn’t suffer relevant injury under
Massachusetts Chapter 93A.  Even
allegations that Mulder was “induced” to travel to a Kohl’s store by false
advertising and that she therefore suffered a resulting economic injury in the
form of travel expenses wasn’t good enough. 
She didn’t explain how deceptive statements on a price tag could have
caused her to travel to Kohl’s in the first place, and didn’t identify other
deceptive ads with the requisite specificity.
A false sense of value isn’t the requisite identifiable
injury, distinct from the claimed deceptive conduct itself, required by
Massachusetts law. “[A]bsent allegations of real loss grounded in some
objective measure, [an] ‘induced purchase’ theory of injury is simply the ‘per
se’ theory of injury in new clothing.”  So too with the “induced travel” theory,
which, if accepted, “would render meaningless the SJC’s clear rule against ‘per
se’ or ‘deception-as-injury’ claims.”
The same conclusions are also provided in Shaulis v.
Nordstrom, Inc., — F.3d –, 2017 WL 3167619, No. 15-2354 (1st Cir.
Jul. 26, 2017). Shaulis argued that the sweater she bought, allegedly due to
the price misrepresentation, was “worth nothing at all to [her] since she never
would have bought it” absent Nordstrom’s deception. But she received the
benefit of her bargain, and didn’t allege that there were flaws in the sweater
that made it worth less than what she paid. 
Subjective belief in value isn’t a legally cognizable injury under
Chapter 93A.
Of possible interest: the court of appeals rejected Shaulis’
analogy to “fake-Rolex hawking” because “falsely advertising a watch as a ‘Rolex’
is a material misstatement about the watch’s quality.”  But this is obviously insufficient as a
distinction!  According to Shaulis’
complaint, so was the discount claim—and the court of appeals supposedly
accepts her claim that she was materially misled (that is, that she changed her
behavior because of the misrepresentation). 
Why then is not a factual inquiry required to determine whether the fake
Rolex-buyer received the benefit of her bargain?  Arguably there is a drop in resale price once
the fakery is revealed—but if the initial price were low enough, that shouldn’t
matter.  The point being that the court
of appeals carefully distinguishes deception from injury when it comes to the
price representations, but not when it comes to the fake Rolex, because
trademark is different.
The court of appeals did note that Shaulis might well have
inferred greater value from the deceptive price tag, and that Nordstrom could
have hoped that consumers would make that inference.  “Indeed, it is presumably just this kind of
erroneous inference that Massachusetts seeks to prevent by regulation.”  Still, that doesn’t mean there was injury
under Chapter 93A. This essentially means that there is no private cause of
action, because without injury there can’t be injunctive relief either, for
conduct banned by Massachusetts consumer protection law.  But the AG can still enforce the law.

Shaulis’s common law claims — for fraud, unjust enrichment,
and breach of contract – failed for basically the same reasons.

from Blogger http://ift.tt/2uGN8DM

Posted in Uncategorized | Tagged , , , | Leave a comment